
|Articles|January 15, 2005
FDA Approves Macugen
The FDA approved pegaptanib sodium injection (Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics) for the treatment of neovascular age-related macular degeneration (AMD) on Dec. 17.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
3
Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists
4
Study identifies 6 key genes linking air pollution to dry eye disease
5


















































.png)


